WinWire Accelerates Pharmaceutical Drug Discovery with Generative AI Solutions
WinWire Technologies partnered with a leading pharmaceutical company to drive digital transformation and accelerate drug discovery using Microsoft Azure’s advanced AI and cloud suite. The challenge stemmed from the need to modernize legacy IT infrastructure, accelerate AI adoption, and maintain operational agility in highly competitive, regulated healthcare environments. Through a mix of strategic consulting and technical implementation, WinWire migrated the client’s data platforms to Azure, enabling secure, scalable cloud infrastructure across the organization. Microsoft Azure OpenAI and Microsoft Copilot Studio were leveraged to build custom Copilots and large language model-powered applications tailored for pharmaceutical R&D and operations. Specific use cases included speeding up drug discovery processes using synthetic data and AI-enabled decision support, optimizing business processes through tailored automation and analytics in Power BI, and orchestrating cloud migrations from legacy or competing platforms (such as AWS or GCP) to Microsoft Azure. The initiative led to faster innovation cycles, improved patient care, significant operational efficiencies, and a secure modern data platform to support pharmaceutical innovation and compliance. WinWire’s capabilities were further helped by Microsoft incentive programs to ensure rapid customer adoption. The case illustrates how holistic cloud transformation, coupled with generative AI and Copilot development, enables rapid business value delivery in pharmaceuticals and healthcare.
- Organization
- WinWire Technologies
- Industry
- Pharma
- Location
- Global
Reported outcomes
Strategic outcomes
Primary read
Use case focus
Showing 3 of 4
- 1AI-Enabled Drug Discovery with Synthetic Data
- 2Custom Copilots for Pharmaceutical Research
- 3Cloud Migration for Pharma IT Modernization
- Slow time-to-market for new drugs due to inefficient, legacy IT systems.
- Difficulty in adopting and scaling AI transformation initiatives within pharma.
- Complex, risk-prone migrations from competing cloud and analytics platforms.
- Need for industry-specific AI applications that ensure compliance and improve quality of patient care.
- Modernized pharmaceutical client’s data and application infrastructure by migrating to Microsoft Azure.
- Developed AI-infused applications and custom Copilots with Azure OpenAI and Microsoft Copilot Studio.
- Used synthetic data and AI-driven decision support to expedite drug discovery.
- Automated analytics with Power BI and orchestrated cloud-to-cloud migrations.
- Guided adoption strategy leveraging Microsoft funding programs.
- Accelerated drug discovery with AI-powered decision-making and synthetic data.
- Improved operational efficiency and speed of innovation in pharmaceutical research.
- Faster and more secure cloud migrations.
- Enhanced quality of patient care and compliance in regulated environments.
Architecture
WinWire built a generative AI platform on Azure, migrating data and applications from legacy and competing cloud vendors. AI-infused applications with Azure OpenAI and Copilot Studio were deployed for drug discovery and operations. Analytics and reporting migrated from Tableau to Power BI. The new architecture optimizes research, reduces manual intervention, and enables secure, compliant IT for the customer.
Sources & evidence1
AI-generated summary. Verify important details with the linked sources before relying on this case.
Explore related AI use cases
Was this useful?